Double-Blind Placebo Controlled Oral Analgesic Comparison of Butorphanol and Pentazocine in Patients with Moderate to Severe Post-Operative Pain

1973 ◽  
Vol 1 (2) ◽  
pp. 422-428
Author(s):  
Robert E S Young
Keyword(s):  
The Other ◽  
Dose Effect ◽  
Surgical Patients ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Oral Analgesic ◽  
Post Operative Pain ◽  
Maximum Pain ◽  
Better Than ◽  
Observation Period

A double-blind, randomized trial was conducted in 120 post-surgical patients to evaluate the oral analgesic activity of butorphanol tartrate (4 mg and 8 mg) and pentazocine HCl (50 mg) as compared to placebo. Both doses of butorphanol as well as pentazocine proved to be significantly (p <0.05) more effective than placebo. Butorphanol 4 mg and pentazocine 50 mg were never significantly different from each other, while butorphanol 8 mg was significantly better than both butorphanol 4 mg as well as pentazocine 50 mg in several instances, demonstrating a significant dose effect relationship for butorphanol. All of the active treatments provided maximum pain relief within 1 to 2 hours and were effective over 4 hours. In contrast to the other treatments, none of the 8 mg butorphanol patients required remedication during the 4-hour observation period. Generally, the incidence of side-effects appeared low.

scholarly journals Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Jessica Ailani ◽  
J. Scott Andrews ◽  
Mallikarjuna Rettiganti ◽  
Robert A. Nicholson
Keyword(s):  
Chronic Migraine ◽  
Migraine Headache ◽  
Pain Severity ◽  
Life Questionnaire ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Link Type ◽  
Total Pain ◽  
Maximum Pain ◽  
The Impact

Abstract Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pain burden and treatment response in patients with episodic migraine (EM) or chronic migraine (CM). The impact of galcanezumab versus placebo on TPB among patients with EM or CM was analyzed. Methods Patients from randomized, double-blind, placebo-controlled episodic (two 6-month studies pooled) and chronic migraine (3-month) studies received once-monthly subcutaneous injection of galcanezumab 120 mg or placebo. A post hoc analysis of TPB for a given month was calculated as severity-weighted duration by multiplying duration (hours) and maximum pain severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) of migraine for each day and summing these over the days in a month. Least square mean change from baseline in monthly TPB across Months 1–6 (EM, N = 444 galcanezumab, N = 894 placebo) and Months 1–3 (CM, N = 278 galcanezumab, N = 558 placebo) were compared using a mixed-model repeated measures model. Correlation of the Migraine Specific Quality of Life Questionnaire (MSQ) and Migraine Disability Assessment Scale (MIDAS) to TPB at baseline was assessed. Results At baseline, the duration of migraine on a given migraine headache day accounted for the greatest unique proportion of variability (EM, 57.4% and CM, 61.1%) to TPB after adjusting for frequency of migraine headache days and maximum pain severity. The decrease from baseline in monthly TPB was greater with galcanezumab than placebo for patients with EM (68.6 versus 36.2) and CM (102.6 versus 44.4). The average percent reduction of TPB from baseline was significantly greater with galcanezumab compared with placebo in patients with EM (50.8% versus 17.2%) and CM (29.7% versus 11.0%). In patients with EM and CM, TPB correlated with MSQ total score (r = − 0.35 and r = − 0.37) and MIDAS (r = 0.34 and r = 0.32). Conclusions Greater reduction in TPB was seen in patients with EM and CM treated with galcanezumab 120 mg once-monthly injection relative to placebo. Discussing TPB supports patient-centric conversations regarding treatment expectations when clinicians are evaluating options for migraine prevention. Trial registration ClinicalTrials.gov: #NCT02614183 (I5Q-MC-CGAG; EVOLVE-1), #NCT02614196 (I5Q-MC-CGAH; EVOLVE-2), and #NCT02614261 (I5Q-MC-CGAI; REGAIN) – all 3 trials were registered on 23 November 2015.

Efficacy of Nimodipine in the Prophylaxis of Migraine

Cephalalgia ◽  
1985 ◽  
Vol 5 (1) ◽  
pp. 39-43 ◽  
Author(s):  
H Havanka-Kanniainen ◽  
E Hokkanen ◽  
VV Myllylä
Keyword(s):  
Side Effects ◽  
Drug Treatment ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Final Value ◽  
Prophylactic Drug ◽  
Better Than

The efficacy of nimodipine in the prophylaxis of migraine was assessed in a double-blind, placebo-controlled, cross-over study carried out on 33 patients, 20 of whom suffered from classic and 13 from common migraine. Four patients dropped out, but not as a result of the side effects of the drug. The duration of drug treatment was 8 weeks. The dosage used was 30 mg four times daily. Nimodipine proved to be better than placebo, the number of migraine attacks and severity of headache showing a significant reduction. The drug was well tolerated and no marked side effects were noted. The results suggest that nimodipine is a useful new prophylactic drug for migraine, but further studies are needed before its final value can be evaluated.

RETRACTED: A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Anti-inflammatory Effects of Ketamine in Cardiac Surgical Patients

2006 ◽  
Vol 20 (2) ◽  
pp. 217-222 ◽  
Author(s):  
Cristian Bartoc ◽  
Robert J. Frumento ◽  
Maya Jalbout ◽  
Elliott Bennett-Guerrero ◽  
Evelyn Du ◽  
...  
Keyword(s):  
Surgical Patients ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Anti Inflammatory

Tramadol in the management of post-operative pain: a double-blind, placebo- and active drug-controlled study

1997 ◽  
Vol 14 (6) ◽  
pp. 646-654 ◽  
Author(s):  
U. M. Stamer ◽  
C. Maier ◽  
S. Grond ◽  
B. Veh-Schmidt ◽  
E. Klaschik ◽  
...  
Keyword(s):  
Active Drug ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Post Operative Pain

Is the routine use of antibiotics justified in adult tonsillectomy?

2003 ◽  
Vol 117 (5) ◽  
pp. 382-385 ◽  
Author(s):  
B. J. O’Reilly ◽  
S. Black ◽  
J. Fernandes ◽  
J. Panesar
Keyword(s):  
General Practitioner ◽  
Pain Score ◽  
Prospective Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Post Operative Pain ◽  
Perioperative Antibiotics ◽  
Secondary Haemorrhage ◽  
Gp Visits ◽  
Adult Tonsillectomy

Pain and secondary haemorrhage are the commonest complications of adult tonsillectomy, occurring mostly in the community. This is a randomized, double-blind, placebo-controlled, prospective trial of the effect of perioperative amoxycillin on these complications. The incidence and severity of post-operative haemorrhage was measured. For the first 10 post-operative days patients provided a linear pain score, a record of GP visits, and their use of additional antibiotics and analgesics.Of 95 patients considered: 23 suffered a secondary haemorrhage; 54 consulted their general practitioner (GP) because of pain; additional antibiotics were used by at least 31 and additional analgesics by at least 41. No significant differences were demonstrated between the active and placebo groups for any of these measures.This study demonstrates that secondary haemorrhage is common after adult tonsillectomy. Post-operative pain remains a major problem requiring frequent GP consultations. There appears to be no justification for the routine use of perioperative antibiotics.

Sign in / Sign up

Export Citation Format

Share Document